Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE:LLY) has announced plans to construct a $6.5 billion manufacturing facility in Houston, Texas, marking its eighth U.S. manufacturing site since 2020. The next-generation synthetic medicine facility will focus on producing small molecule medicines, including the company's oral GLP-1 receptor agonist, orforglipron.
The facility will create 615 high-wage jobs and generate 4,000 construction jobs. Expected to be operational within five years, it will be equipped with advanced technologies including AI, machine learning, and digital automation. The Houston site, selected from over 300 applications, represents one of four new U.S. manufacturing sites Lilly plans to announce this year.
Eli Lilly (NYSE:LLY) announced positive Phase 3 trial results for Mounjaro (tirzepatide) in children and adolescents with type 2 diabetes. The SURPASS-PEDS trial demonstrated that Mounjaro achieved superior A1C reduction of 2.2% from baseline compared to placebo at 30 weeks.
Key highlights include 86.1% of participants on 10mg dose achieving target A1C of ≤6.5%, and an average BMI reduction of 11.2%. The safety profile was consistent with adult studies, with mainly mild-to-moderate gastrointestinal side effects. These results have been submitted to global regulatory agencies for an expanded indication.
Eli Lilly (NYSE:LLY) announced positive topline results from ACHIEVE-3, a Phase 3 head-to-head trial comparing its oral GLP-1 drug orforglipron against oral semaglutide in 1,698 adults with type 2 diabetes. The 52-week trial demonstrated orforglipron's superiority, with the highest dose (36mg) achieving a 2.2% A1C reduction versus 1.4% with oral semaglutide's highest dose (14mg).
In key secondary endpoints, orforglipron 36mg showed 73.6% greater relative weight loss, with patients losing an average of 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14mg. Notably, 37.1% of participants on the highest orforglipron dose achieved near-normal blood sugar (A1C <5.7%) versus 12.5% for oral semaglutide. Lilly plans to submit orforglipron for regulatory approval in 2026.
Eli Lilly (NYSE:LLY) announced Phase 3 ATTAIN-1 trial results for orforglipron, an investigational oral GLP-1 receptor agonist for obesity treatment. The once-daily pill demonstrated significant weight loss, with participants taking the highest dose (36mg) achieving an average reduction of 27.3 lbs (12.4%) at 72 weeks.
Key findings include: 59.6% of participants on the highest dose lost ≥10% body weight, 39.6% lost ≥15%, and among participants with prediabetes, up to 91% achieved near-normal blood sugar levels compared to 42% on placebo. The drug showed meaningful improvements in cardiovascular risk factors, reducing hsCRP levels by 47.7%.
Safety profile aligned with the GLP-1 class, with primarily gastrointestinal-related adverse events. Lilly plans global regulatory submissions for obesity treatment, with potential approval as early as next year, followed by type 2 diabetes submission in 2026.
Eli Lilly (NYSE:LLY) has announced plans to construct a $5 billion manufacturing facility in Goochland County, Virginia, marking the first of four planned U.S. manufacturing sites to be announced this year. The facility will be the company's first dedicated, fully integrated site for producing active pharmaceutical ingredients (API) and drug products for bioconjugates and monoclonal antibodies.
The project will create 650 high-paying permanent jobs and 1,800 construction jobs, with completion expected within five years. The facility will focus on manufacturing antibody-drug conjugates (ADCs) and is part of Lilly's $50 billion U.S. capital expansion commitment since 2020. For every dollar invested, the company expects to generate up to four dollars in local economic activity.
Eli Lilly (NYSE:LLY) announced its participation in Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. The company's CFO, Lucas Montarce, will participate in a fireside chat at 8:00 AM ET.
Investors can access a live audio webcast through Lilly's investor website, with a replay available for approximately 90 days following the event.
Eli Lilly (NYSE:LLY) has launched "Brain Health Matters," a global campaign aimed at promoting proactive brain health and early detection of Alzheimer's disease. The company has partnered with acclaimed actress Julianne Moore to raise awareness, particularly among women who represent nearly two-thirds of Alzheimer's diagnoses.
The multi-year campaign builds on 35 years of brain health research and comes as statistics show that 13.8 million people aged 65 and older are projected to have Alzheimer's dementia by 2060. The initiative emphasizes early intervention, noting that Alzheimer's can begin up to 20 years before symptoms appear. The campaign will run across U.S. television, digital, and audio platforms, with plans for global expansion.
Eli Lilly (NYSE:LLY) has launched Lilly TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on Lilly's extensive research data valued at over $1 billion. The platform, part of Lilly Catalyze360's offerings, employs federated learning to allow biotechs to utilize Lilly's AI capabilities while protecting proprietary data.
The platform is trained on comprehensive datasets including drug disposition, safety, and preclinical data from hundreds of thousands of unique molecules. Partner companies will contribute training data to continuously improve the ecosystem. Future releases will include in vivo small molecule predictive models available exclusively on TuneLab.
Eli Lilly (NYSE:LLY) announced positive topline results from its Phase 3 BRUIN CLL-313 trial of Jaypirca (pirtobrutinib) in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study demonstrated statistically significant improvement in progression-free survival compared to chemoimmunotherapy in treatment-naïve patients.
The trial achieved its primary endpoint with one of the most compelling effect sizes observed for a single-agent BTK inhibitor in front-line CLL studies. While overall survival data is not yet mature, it shows strong positive trends. This marks Jaypirca's third positive Phase 3 study, with global regulatory submissions for label expansions planned to begin in late 2025.
Eli Lilly (NYSE:LLY) announced that its drug olomorasib has received FDA Breakthrough Therapy designation for first-line treatment of certain metastatic non-small cell lung cancer (NSCLC) patients. The designation applies to olomorasib in combination with KEYTRUDA for patients with unresectable advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 expression ≥ 50%.
The designation is based on promising results from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial. Olomorasib is described as a potent and selective second-generation KRAS G12C inhibitor with preliminary evidence of central nervous system activity. Updated efficacy and safety data will be presented at the upcoming IASLC 2025 World Conference on Lung Cancer in Barcelona, featuring integrated analyses from multiple clinical trials.